{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-275461","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.122037+00:00","generated_at":"2026-06-08T04:53:23.509240+00:00","sec_items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Selecta completes merger with Cartesian; renamed Cartesian Therapeutics, ticker RNAC","bullets":["Merger closed Nov 13; Selecta issued 6.7M common shares and 384,931 Series A Preferred to Cartesian holders.","Insider PIPE of $60.25M from board member Springer and former CEO Kalayoglu trust; 149,330 Series A Preferred sold.","New officers appointed: Metin Kurtoglu (COO), Milos Miljkovic (CMO), Chris Jewell (CSO); former CMO/CSO/COO resigned.","CVRs to be issued to Selecta stockholders, entitling them to 100% of future Sobi license milestones/royalties.","Series A Preferred convertible into 1,000 common shares each, subject to stockholder approval of charter amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-275461","json":"https://secwatch.observer/filing/0001193125-23-275461.json","markdown":"https://secwatch.observer/filing/0001193125-23-275461.md","text":"https://secwatch.observer/filing/0001193125-23-275461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:53:23.509240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d3857e35b","claim":"Lloyd Johnston resigned as Chief Operations Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operations Officer"}],"fact_type":"executive_change"},{"claim_id":"16e412976b","claim":"Chris Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"51d728b615","claim":"Peter Traber resigned as Chief Medical Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"70ff266f0d","claim":"Kei Kishimoto resigned as Chief Scientific Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"8bbeb4171d","claim":"Milos Miljkovic was appointed as Chief Medical Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"b57223a493","claim":"Metin Kurtoglu was appointed as Chief Operating Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"39f0c0df7a932a1fd2a06240920e0ae43ef180db","claim":"Cartesian Therapeutics, Inc.: Company amended its restated certificate of incorporation to change corporate name to Cartesian Therapeutics, Inc (effective 2023-11-13).","evidence_excerpt":"On November 13, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to the Charter to change its corporate name to Cartesian Therapeutics, Inc.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-13"}],"fact_type":"governance_change"},{"claim_id":"02e0ec24906f9aa40a0b65588c73ef69d9d6dccc","claim":"Cartesian Therapeutics, Inc. completed an acquisition involving Cartesian Therapeutics, Inc. for 6,723,662 shares of the common stock of Selecta and 384,930.725 shares of Series A Preferred Stock (closed 2023-11-13).","evidence_excerpt":"Agreement and Plan of Merger On November 13, 2023, Selecta Biosciences, Inc., a Delaware corporation (“Selecta” or the “Company”), acquired Cartesian Therapeutics, Inc., a Delaware corporation (“Cartesian”), in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the “Merger Agreement”), by and among Selecta, Sakura Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Selecta (“First Merger Sub”), Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Selecta (“Second Merger Sub”), and Cartesian.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Cartesian Therapeutics, Inc."},{"label":"Consideration","value":"6,723,662 shares of the common stock of Selecta and 384,930.725 shares of Series A Preferred Stock"},{"label":"Closing","value":"2023-11-13"}],"fact_type":"ma_transaction"},{"claim_id":"b040f29f11dab0acfb22c60ac18ce3ade3569b6c","claim":"Cartesian Therapeutics, Inc. entered into Merger Agreement with Selecta Biosciences, Inc..","evidence_excerpt":"Pursuant to the Merger Agreement, Selecta has agreed to hold a stockholders’ meeting to submit the following matters to its stockholders for their consideration","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Selecta Biosciences, Inc."}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}